Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Corinne Lehmann is active.

Publication


Featured researches published by Corinne Lehmann.


The Journal of Infectious Diseases | 2012

Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial

Hana M. El Sahly; Charles E. L. B. Davis; Karen L. Kotloff; Jeffery L. Meier; Patricia L. Winokur; Anna Wald; Christine Johnston; Sarah L. George; Rebecca C. Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A. Keitel

BACKGROUND The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HIV)-infected individuals has not been fully explored. METHODS One hundered ninety-two HIV-infected individuals aged 18-64 years were stratified by CD4 cell count (<200 cells/mL or ≥200 cells/mL) and randomized to receive 2 doses of 15 μg or 30 μg HA 2009 H1N1 vaccine 21 days apart. Hemagglutination inhibition (HAI) and microneutralization (MN) antibodies were measured on days 0, 10, 21, 31, 42, and 201. RESULTS Recipients of 30 μg HA had significantly higher HAI geometric mean titers (GMTs), compared with recipients of 15 μg HA on days 10 (139.0 vs 51.9; P = .01), 21 (106.7 vs 51.9; P = .001), and 31 (130.0 vs 73.7; P = .03) but not on days 42 (91.8 vs 61.6; P = .11) and 201 (43.0 vs 27.0; P = .08). When analyzed by CD4 cell count stratum, HAI GMTs were significantly higher among 30 μg HA recipients than among 15 μg HA in the CD4 cell count <200 cells/mL stratum on days 21 and 31 and the MN GMTs on days 10, 21, 31, and 42 (P < .05). In the CD4 cell count ≥200 cells/mL stratum, MN GMTs were significantly higher among recipients of 30 μg HA than among recipients of 15 μg HA on day 10 (P = .03). CONCLUSION Increasing the HA dose of the 2009 H1N1 vaccine improves the vaccines immunogenicity in HIV-infected individuals. CLINICAL TRIALS REGISTRATION NCT00992433.


Clinical Pediatrics | 2009

Vaccine Adherence in Adolescents

Corinne Lehmann; Paul A. S. Benson

Although a number of routine and catch-up vaccinations are currently recommended for adolescents, coverage rates of these vaccines are currently suboptimal. Routine recommended immunizations for this cohort include vaccines for influenza, human papillomavirus, and meningococcal disease, as well as a booster for tetanus, diphtheria, and acellular pertussis. Adolescence is also a critical period for administration of catch-up vaccines for those not fully immunized during childhood. Adolescents who do not seek appropriate preventive healthcare are at risk for significant morbidity and possible mortality. Increasing adolescent adherence to recommended vaccine schedules presents a challenge and opportunity for pediatricians and public health advocates. This article outlines barriers to vaccine compliance among adolescents and discusses strategies to increase vaccine uptake.


JAMA Pediatrics | 2010

Changes in human immunodeficiency virus testing rates among urban adolescents after introduction of routine and rapid testing.

Tanya L. Kowalczyk Mullins; Linda M. Kollar; Corinne Lehmann; Jessica A. Kahn

OBJECTIVES To examine human immunodeficiency virus (HIV) testing rates among adolescents during a 3-year period to determine (1) if the rate of testing increased after publication of national recommendations for routine HIV testing in 2006, and again after the introduction of rapid testing in the clinic in 2007, and (2) factors associated with HIV testing. DESIGN Retrospective medical record review. SETTING Urban hospital-based adolescent primary care clinic. PARTICIPANTS Thirteen- to 22-year-old sexually experienced patients who had computerized billing data reflecting testing for sexually transmitted infections, including HIV. OUTCOME MEASURES Rates of HIV testing for each of 3 one-year phases-phase 1 (pre-routine testing recommendations), phase 2 (post-routine testing recommendations but pre-rapid testing), and phase 3 (post-rapid testing)-and factors associated with HIV testing. RESULTS In total, 9491 patients were included. The rate of HIV testing in phase 2 was significantly higher than the rate of testing in phase 1 (27.7% vs 12.6%, P < .001). The rate of testing in phase 3 was significantly higher than the rate of testing in phase 2 (44.6% vs 27.7%, P < .001) and phase 1 (P < .001). Factors independently associated with HIV testing included phase, older age, male sex, race, public insurance status, and having a genitourinary-related diagnosis during the same phase. CONCLUSIONS The HIV testing rates increased significantly following publication of recommendations for routine testing and further increased following introduction of rapid testing. Combining routine and rapid testing strategies may increase uptake of HIV testing among adolescents in primary care settings.


Pediatric Drugs | 2016

Adolescent Vaccination Strategies: Interventions to Increase Coverage.

Corinne Lehmann; Rebecca C. Brady; Reuben Oneal Battley; Jennifer L. Huggins

While vaccines have decreased the burden of disease, many adolescents still remain under-immunized, particularly for human papillomavirus (HPV) and influenza. We review the most current data regarding adolescent immunizations in the United States and discuss proven strategies that work for increasing vaccination rates. Strategies that have been shown to improve rates include provider feedback, immunization information systems (or registries), and enhanced access outside of provider offices, such as school-based immunization programs. Overall, practices may want to consider multimodal quality improvement approaches to enhance practice vaccination rates. The public health and cost benefits of immunizing adolescents are well known, yet recent measles outbreaks in the United States have highlighted issues with state immunization laws and vaccine refusals. Providers should be clear in their advice regarding vaccines and use effective reminder strategies as parents commonly cite not having enough information or knowledge that a vaccine was needed for their adolescent. Additional research is needed regarding adolescent consent for vaccines, as well as adolescent and parental refusal, in order to design systems that will help inform families and allow for widespread vaccine availability.


Current Pediatrics Reports | 2018

Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults

Tanya L. Kowalczyk Mullins; Corinne Lehmann

Purpose of ReviewTo review the literature about oral pre-exposure prophylaxis (PrEP) for HIV prevention, with specific focus on adolescents.Recent FindingsUse of PrEP reduces new HIV infections among men who have sex with men, heterosexuals, and people who inject drugs. One combination antiretroviral medication is approved for PrEP in the USA for adults. Limited data suggest that PrEP is safe for use in youth, although declines in adherence to PrEP over time suggest the need for adherence interventions specifically targeting youth. Safety concerns related to PrEP include potential negative impacts on bone density and renal function, as well as potential increases in riskier sexual behaviors. The U.S. Public Health Service has published guidelines for PrEP use in adults.SummaryCurrent data suggest that PrEP use is safe in adolescents; however, further research is needed on the potential impact of long-term PrEP use on bone density and kidney function.


Sexual Health | 2015

Syphilis among adolescents and young adults in Cincinnati, Ohio: testing, infection and characteristics of youth with syphilis infection

Sherine A. Patterson-Rose; Tanya L. Kowalczyk Mullins; Elizabeth A. Hesse; Corinne Lehmann; Lea E. Widdice

Little is known about the epidemiology of syphilis among adolescents and young adults. This study examined, among more than 17000 young people aged 13-22 years old, trends in rates of syphilis testing and infection; characteristics of infected adolescents; and agreement about syphilis staging and treatment between provider and chart reviewer. Rates of syphilis testing increased but rates of syphilis infection did not increase significantly over a 5-year period. A majority of infected men reported only opposite-sex sexual contact. High agreement between providers and chart reviewers was found. These findings demonstrate the need for complete assessment of risk factors and use of local epidemiology in screening practices.


The Journal of Infectious Diseases | 2012

Editor's Choice: Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial

Hana M. El Sahly; Charles E. Davis; Karen L. Kotloff; Jeffery L. Meier; Patricia L. Winokur; Anna Wald; Christine Johnston; Sarah George; Rebecca C. Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A. Keitel

BACKGROUND The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HIV)-infected individuals has not been fully explored. METHODS One hundered ninety-two HIV-infected individuals aged 18-64 years were stratified by CD4 cell count (<200 cells/mL or ≥200 cells/mL) and randomized to receive 2 doses of 15 μg or 30 μg HA 2009 H1N1 vaccine 21 days apart. Hemagglutination inhibition (HAI) and microneutralization (MN) antibodies were measured on days 0, 10, 21, 31, 42, and 201. RESULTS Recipients of 30 μg HA had significantly higher HAI geometric mean titers (GMTs), compared with recipients of 15 μg HA on days 10 (139.0 vs 51.9; P = .01), 21 (106.7 vs 51.9; P = .001), and 31 (130.0 vs 73.7; P = .03) but not on days 42 (91.8 vs 61.6; P = .11) and 201 (43.0 vs 27.0; P = .08). When analyzed by CD4 cell count stratum, HAI GMTs were significantly higher among 30 μg HA recipients than among 15 μg HA in the CD4 cell count <200 cells/mL stratum on days 21 and 31 and the MN GMTs on days 10, 21, 31, and 42 (P < .05). In the CD4 cell count ≥200 cells/mL stratum, MN GMTs were significantly higher among recipients of 30 μg HA than among recipients of 15 μg HA on day 10 (P = .03). CONCLUSION Increasing the HA dose of the 2009 H1N1 vaccine improves the vaccines immunogenicity in HIV-infected individuals. CLINICAL TRIALS REGISTRATION NCT00992433.


The Journal of Infectious Diseases | 2012

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults

Hana M. El Sahly; Charles E. L. B. Davis; Karen L. Kotloff; Jeffery L. Meier; Patricia L. Winokur; Anna Wald; Christine Johnston; Sarah George; Rebecca C. Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A. Keitel

BACKGROUND The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HIV)-infected individuals has not been fully explored. METHODS One hundered ninety-two HIV-infected individuals aged 18-64 years were stratified by CD4 cell count (<200 cells/mL or ≥200 cells/mL) and randomized to receive 2 doses of 15 μg or 30 μg HA 2009 H1N1 vaccine 21 days apart. Hemagglutination inhibition (HAI) and microneutralization (MN) antibodies were measured on days 0, 10, 21, 31, 42, and 201. RESULTS Recipients of 30 μg HA had significantly higher HAI geometric mean titers (GMTs), compared with recipients of 15 μg HA on days 10 (139.0 vs 51.9; P = .01), 21 (106.7 vs 51.9; P = .001), and 31 (130.0 vs 73.7; P = .03) but not on days 42 (91.8 vs 61.6; P = .11) and 201 (43.0 vs 27.0; P = .08). When analyzed by CD4 cell count stratum, HAI GMTs were significantly higher among 30 μg HA recipients than among 15 μg HA in the CD4 cell count <200 cells/mL stratum on days 21 and 31 and the MN GMTs on days 10, 21, 31, and 42 (P < .05). In the CD4 cell count ≥200 cells/mL stratum, MN GMTs were significantly higher among recipients of 30 μg HA than among recipients of 15 μg HA on day 10 (P = .03). CONCLUSION Increasing the HA dose of the 2009 H1N1 vaccine improves the vaccines immunogenicity in HIV-infected individuals. CLINICAL TRIALS REGISTRATION NCT00992433.


Journal of Adolescent Health | 2018

The Depression Curriculum: Primary Care, Case-Based Training on Caring for Adolescents with Depression From Screening to Pharmaceutical Management

Michael D. Colburn; Emily S. Harris; Melissa Klein; Corinne Lehmann


Practical Pediatric and Adolescent Gynecology | 2013

Adolescent Preventive Care for Healthy Teens

Kristin L. Kaltenstadler; Corinne Lehmann

Collaboration


Dive into the Corinne Lehmann's collaboration.

Top Co-Authors

Avatar

Rebecca C. Brady

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Anna Wald

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hana M. El Sahly

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tanya L. Kowalczyk Mullins

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Wendy A. Keitel

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Bin Huang

Cincinnati Children's Hospital Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge